Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

4.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

24.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.8K
MicroRNAs01:22

MicroRNAs

12.1K
12.1K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.7K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same author

Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition.

Molecular therapy. Oncology·2026
Same author

Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus.

Molecular therapy. Advances·2026
Same author

Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.

Cell reports. Medicine·2024
Same author

Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification.

Molecular therapy. Oncology·2024

Related Experiment Video

Updated: Apr 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

MicroRNAs and oncolytic viruses.

Autumn J Ruiz1, Stephen J Russell1

  • 1Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, United States.

Current Opinion in Virology
|April 13, 2015
PubMed
Summary

MicroRNAs control gene expression and can be engineered into oncolytic viruses to target cancer. This strategy enhances therapeutic efficacy and safety for potent cancer treatment.

Area of Science:

  • Molecular Biology
  • Genetics
  • Virology

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression in mammals, often showing tissue-specific patterns.
  • Oncolytic viruses (OVs) are engineered to selectively infect and kill cancer cells.
  • Targeting strategies are crucial for enhancing the safety and efficacy of OV-based therapies.

Purpose of the Study:

  • To explore the use of miRNA target sequences for tissue-specific control of gene expression and viral tropism.
  • To investigate the combination of miRNA regulation with oncolytic virotherapy for improved cancer treatment.
  • To enhance the therapeutic index of oncolytic viruses and miRNA-based therapeutics.

Main Methods:

  • Incorporating miRNA target sequences into exogenous genes and viral genomes.

More Related Videos

MicroRNA-based Regulation of Picornavirus Tropism
09:05

MicroRNA-based Regulation of Picornavirus Tropism

Published on: February 6, 2017

8.1K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.6K

Related Experiment Videos

Last Updated: Apr 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
MicroRNA-based Regulation of Picornavirus Tropism
09:05

MicroRNA-based Regulation of Picornavirus Tropism

Published on: February 6, 2017

8.1K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.6K
  • Developing unattenuated oncolytic viruses with enhanced potency and broad tropisms.
  • Utilizing oncolytic viruses to deliver and enhance miRNA-based therapeutics (restorative or inhibitory).

    • Main Results:

    • Engineered oncolytic viruses demonstrated enhanced potency and reduced off-target toxicities in multiple tissues.
    • The strategy allowed for simultaneous control of gene expression and viral tropism in specific tissues.
    • Combination therapy showed increased delivery, duration, and therapeutic efficacy of miRNA-based treatments.

    Conclusions:

    • Combining oncolytic virotherapy with miRNA regulation represents a potent and safe approach for cancer therapeutics.
    • This strategy offers precise control over gene expression and viral targeting, improving therapeutic outcomes.
    • Further development holds promise for next-generation cancer treatments with enhanced specificity and reduced side effects.